Dyadic, Sanofi Pasteur, EnGen Bio ink R&D deal

In the Netherlands, the Dutch-based R&D subsidiary of Dyadic International has entered into an research agreement with Sanofi Pasteur, the vaccines division of sanofi-aventis Group, and EnGen Bio, Inc. Under the agreement, Sanofi Pasteur will fund collaborative research at Dyadic Netherland’s research and development facility in Wageningen, The Netherlands, which will utilize Dyadic’s proprietary and patented C1 Platform Technology for certain vaccine applications. The research will be conducted under the guidance and direction of Dyadic Netherland’s General Manager, Dr. ir. Wim van der Wilden, with coordination by Dr. Mark Alfenito, the President and CEO of EnGen Bio. The research is anticipated to be completed in six to twelve months. All other terms of the research collaboration are confidential.